2021 forecast: Clinical trial diversity has long been a thorn in biopharma's side, but 2020 could turn things around

It seems like a no-brainer. If a company wants to treat everyone who has a certain disease with its new drug, then it should test that drug in, well, everyone.

But that isn’t always the case, even today. This summer, researchers called out Gilead Sciences for failing to “provide equal representation of Black, Latinx and Native Americans” in its clinical trials for Veklury, the first FDA-approved treatment for COVID-19.